The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data
- PMID: 28808596
- PMCID: PMC5541810
- DOI: 10.1155/2017/6516401
The Severity of Intracranial Hemorrhages Measured by Free Hemoglobin in the Brain Depends on the Anticoagulant Class: Experimental Data
Abstract
Background and Purpose. Anticoagulant therapy is broadly used to prevent thromboembolic events. Intracranial hemorrhages are serious complications of anticoagulation, especially with warfarin. Direct oral anticoagulants reduce but do not eliminate the risk of intracranial hemorrhages. The aim of this study is to determine the degree of intracranial hemorrhage after application of anticoagulants without additional triggers. Methods. Rats were treated with different anticoagulant classes (vitamin K antagonists, heparin, direct thrombin inhibitor, and factor Xa inhibitor). Brain hemorrhages were assessed by the free hemoglobin concentration in the brain parenchyma. Results. Vitamin K antagonists (warfarin and brodifacoum) significantly increased free hemoglobin in the brain. Among direct oral anticoagulants, thrombin inhibitor dabigatran also significantly increased free hemoglobin in the brain, whereas treatment with factor Xa inhibitor rivaroxaban did not have significant effect on the free hemoglobin concentration. Conclusions. Our data indicates that the severity of brain hemorrhages depends on the anticoagulant class and it is more pronounced with vitamin K antagonists.
Figures


Similar articles
-
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2479-2488. doi: 10.1016/j.jstrokecerebrovasdis.2014.06.031. Epub 2014 Oct 29. J Stroke Cerebrovasc Dis. 2014. PMID: 25440361 Review.
-
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.Neurol Neurochir Pol. 2015;49(3):171-9. doi: 10.1016/j.pjnns.2015.04.007. Epub 2015 May 7. Neurol Neurochir Pol. 2015. PMID: 26048605 Review.
-
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.Intern Emerg Med. 2017 Dec;12(8):1101-1108. doi: 10.1007/s11739-017-1753-2. Epub 2017 Sep 19. Intern Emerg Med. 2017. PMID: 28929298 Review.
-
[Spontaneous choroidal hemorrhage associated with novel oral anticoagulants: A report of two cases and literature review].J Fr Ophtalmol. 2018 Oct;41(8):767-772. doi: 10.1016/j.jfo.2018.01.007. Epub 2018 Sep 11. J Fr Ophtalmol. 2018. PMID: 30213607 Review. French.
-
New Target-Specific Oral Anticoagulants and Intracranial Bleeding: Management and Outcome in a Single-Center Case Series.World Neurosurg. 2016 Apr;88:132-139. doi: 10.1016/j.wneu.2015.11.086. Epub 2015 Dec 28. World Neurosurg. 2016. PMID: 26732970
Cited by
-
Erythrocytes, a New Contributor to Age-Associated Loss of Blood-Brain Barrier Integrity.Adv Sci (Weinh). 2021 Oct;8(20):e2101912. doi: 10.1002/advs.202101912. Epub 2021 Aug 16. Adv Sci (Weinh). 2021. PMID: 34396716 Free PMC article.
References
-
- Miller C. S., Grandi S. M., Shimony A., Filion K. B., Eisenberg M. J. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. The American Journal of Cardiology. 2012;110(3):453–460. doi: 10.1016/j.amjcard.2012.03.049. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources